ACM
TARA icon

AIGH Capital Management’s Protara Therapeutics TARA Stock Holding History

AIGH Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,622,733
Closed -$8.45M – 55
2026
Q1 		$8.45M Buy
+1,622,733
New +$9.6M 1.15% 24

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

AIGH Capital Management's TARA Position: Q2 2026 in Review

AIGH Capital Management sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 1,622,733 shares — an estimated $8.45M sold.

AIGH Capital Management first reported a position in TARA in Q1 2026 and held it in 1 quarter. The position peaked at $8.45M in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • AIGH Capital Management reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • AIGH Capital Management sold 1,622,733 Protara Therapeutics shares in Q2 2026, an estimated $8.45M.
  • AIGH Capital Management first reported a position in Protara Therapeutics in Q1 2026 and held it in 1 quarter.
  • AIGH Capital Management's Protara Therapeutics position peaked at $8.45M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on AIGH Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.